Compare GeneDx Holdings Corp (WGS) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Wix.Com Ltd — how do they compare? GeneDx Holdings Corp trades at $67.95 (market cap $2.02B), while Wix.Com Ltd trades at $75.04 (market cap $3.11B). The key difference: Wix.Com Ltd is the larger of the two by market cap, and Wix.Com Ltd is more actively traded (809,286 versus 734,640). Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Wix.Com Ltd for 62 Days on average.
| WGS | WIX | |
|---|---|---|
Market Cap | $2.02B | $3.11B |
Volume | 734,640 | 809,286 |
Sector | Health | Technology |
52-Week High | $167.51 | $145.54 |
52-Week Low | $34.51 | $40.43 |
Typical Hold Time | 19 Days | 62 Days |
Enterprise Value | $2.05B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
WIX trades at $75.06, up 2.86% today, near the consensus price target of $77.00. The stock shows mixed technical signals with a neutral overall rating but bullish moving averages. Revenue growth is strong, reaching $1.99 billion in 2025, though net income turned positive only recently. However, negative shareholder equity and a class action lawsuit filed in September 2026 present significant headwinds. Analyst sentiment remains largely positive with 63% buy ratings, but recent earnings misses add caution.
The outlook is cautiously optimistic given solid revenue expansion and analyst support, but high valuation multiples, litigation overhang, and inconsistent profitability pose risks. Investors should weigh growth potential against financial stability concerns and legal uncertainties before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
